SUPPLEMENTARY MATERIAL

**Table 1 of the Supplementary Material.** Factors Associated With Coronary Angiography During Index Hospitalization in NSTEACS Patients in EPICOR. Model Adjusted for Hospital Type (Regional, Non-university General, University General, Private) and Geographical Region, Using a Multi-level Model-adjust For Clustering

|  |  |  |
| --- | --- | --- |
| **Variable** | **Univariate analysis** | **Multivariate analysis\*** |
|  | **No angiography** | **Angiography** | ***P*-Value** | **Odds ratio (95%CI)** | ***P*-Value** |
| **Type of hospital** |  |  |  |  |  |
| Regional hospital | 267 (22.5) | 1022 (23.2) |  | 1.58 (0.68-3.64) |  |
| Non-university general | 379 (32.0) | 1202 (27.3) |  | 0.55 (0.25-1.18) |  |
| University general | 446 (37.6) | 1719 (39.0) |  | 1.00 (reference) |  |
| Private | 94 (7.9) | 462 (10.5) |  | 2.69 (0.80-9.04) |  |
| **Geographical region** |  |  |  |  |  |
| Eastern Europe | 298 (25.1) | 919 (20.9) |  | 0.15 (0.06-0.35) |  |
| Latin America | 392 (33.1) | 602 (13.7) |  | 0.04 (0.02-0.11) |  |
| Western Europe (North) | 311 (26.2) | 1860 (42.2) |  | 1.00 (reference) |  |
| Western Europe (South) | 185 (15.6) | 1024 (23.2) |  | 1.08 (0.47-2.47) |  |
| **Patient characteristics** |  |  |  |  |  |
| NSTEMI | 725 (61.1) | 3248 (73.7) | <.0001 | 1.57 (1.14-2.15) | .0051 |
| Age > 75 years | 346 (29.2) | 766 (17.4) | <.0001 | 0.38 (0.28-0.53) | <.0001 |
| Male | 750 (63.2) | 3226 (73.2) | <.0001 |  |  |
| Hypertension | 874 (74.3) | 2813 (64.7) | <.0001 |  |  |
| Hypercholesterolemia | 617 (55.0) | 2327 (54.7) | .8514 |  |  |
| Diabetes mellitus | 412 (35.2) | 1093 (25.1) | <.0001 |  |  |
| Current smoking | 451 (41.2) | 1396 (34.0) | <.0001 | 0.67 (0.51-0.88) | .0037 |
| Glucose > 160 mg/dL | 294 (26.8) | 729 (19.4) | <.0001 |  |  |
| Serum creatinine > 1.2 mg/dL | 534 (46.9) | 2060 (49.6) | .1024 |  |  |
| Haemoglobin < 13 mg/dL | 401 (35.5) | 923 (22.6) | <.0001 | 0.65 (0.48-0.87) | .0034 |
| Prior CVD | 695 (58.8) | 1965 (45.0) | <.0001 |  |  |
| Prior MI | 428 (36.5) | 1030 (23.7) | <.0001 | 0.56 (0.39-0.78) | .0009 |
| Prior PCI | 195 (16.7) | 967 (22.3) | <.0001 | 1.58 (1.07-2.32) | .0209 |
| Prior CABG | 130 (11.0) | 401 (9.2) | .0568 | 0.60 (0.38-0.94) | .0249 |
| Heart failure | 188 (16.1) | 229 (5.3) | <.0001 | 0.30 (0.19-0.49) | <.0001 |
| Arial fibrillation | 117 (10.0) | 251 (5.8) | <.0001 |  |  |
| TIA/stroke | 98 (8.3) | 267 (6.1) | .007 |  |  |
| PVD | 92 (8.0) | 291 (6.7) | .1262 |  |  |
| Aspirin | 571 (48.2) | 1884 (42.8) | .0009 |  |  |
| Clopidogrel | 211 (17.8) | 621 (14.1) | .0015 |  |  |
| Anticoagulants | 84 (7.1) | 183 (4.2) | <.0001 |  |  |
| ACE inhibitors/ARBs | 645 (54.5) | 1861 (42.4) | <.0001 | 0.70 (0.53-0.92) | .0096 |
| Beta-blocker | 533 (45.0) | 1670 (38.0) | <.0001 |  |  |
| Statins | 473 (40.2) | 1747 (39.7) | .8018 |  |  |
| **Presence of catheterization laboratory in hospital** | 538 (45.4) | 3715 (84.3) | <.0001 | 46.76 (22.40-97.58) | <0.0001 |
| **Terms relating-hospital level clustering** |  |  |  |  |  |
| Standard deviation of random effect term |  |  |  | 2.56 | <0.0001 |

Medications are chronic CV medications (ie, patients were taking these before index event).

\*Terms selected using stepwise variable selection, except hospital type and geographical region, which are forced into the multivariate model

95%CI, 95% confidence interval; ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; CABG, coronary artery bypass graft; CV, cardiovascular; CVD, cardiovascular disease; MI, myocardial infarction; NSTEACS, non-ST-segment elevation acute coronary syndrome; NSTEMI, non-ST-segment elevation myocardial infarction; PAD, peripheral arterial disease; PCI, percutaneous coronary intervention; TIA, transient ischemic attack.

**Table 2 of the Supplementary Material.** Factors Associated With Coronary Revascularization During Index Hospitalization in NSTEACS Patients Who Received Coronary Angiography and Had Significant Coronary Artery Disease. Model Adjusted for Hospital Type (Regional, Non-university General, University General, Private) and Geographical Region, Using A Multi-Level Model-Adjust for Clustering

|  |  |  |
| --- | --- | --- |
| **Variable** | **Univariate analysis** | **Multivariate analysis\*** |
|  | **No angiography** | **Angiography** | ***P*-Value** | **Odds ratio (95%CI)** | ***P*-Value** |
| **Type of hospital** |  |  |  |  |  |
| Regional hospital | 150 (22.4) | 776 (23.6) |  | 1.10 (0.74-1.63) |  |
| Non-university general | 181 (27.1) | 900 (27.4) |  | 1.06 (0.73-1.54) |  |
| University general | 256 (38.3) | 1281 (39.0) |  | 1.00 (reference) |  |
| Private | 82 (12.3) | 328 (10.0) |  | 2.19 (1.14-4.20) |  |
| **Geographical region** |  |  |  |  |  |
| Eastern Europe | 186 (27.8) | 649 (19.8) |  | 0.50 (0.33-0.77) |  |
| Latin America | 137 (20.5) | 386 (11.8) |  | 0.29 (0.18-0.48) |  |
| Western Europe (North) | 236 (35.3) | 1420 (43.2) |  | 1.00 (reference) |  |
| Western Europe (South) | 110 (16.4) | 830 (25.3) |  | 1.10 (0.73-1.66) |  |
| **Patient characteristics** |  |  |  |  |  |
| NSTEMI | 454 (67.9) | 2491 (75.8) | <.0001 |  |  |
| Age > 75 years | 139 (20.8) | 559 (17.0) | .0201 | 0.73 (0.55-0.98) | .0348 |
| Male gender | 484 (72.3) | 2513 (76.5) | .0223 | 1.34 (1.04-1.72) | .0217 |
| Hypertension | 466 (70.4) | 2084 (64.3) | .0026 |  |  |
| Hypercholesterolemia | 399 (61.8) | 1716 (54.2) | .0004 |  |  |
| Diabetes mellitus | 213 (32.1) | 800 (24.7) | .0001 |  |  |
| Current smoking | 221 (35.6) | 996 (32.5) | .1338 |  |  |
| Glucose > 160 mg/dL | 136 (23.4) | 548 (19.4) | .028 |  |  |
| Serum creatinine > 1.2 mg/dL | 319 (50.4) | 1523 (49.1) | .5567 | 0.76 (0.58-0.99) | .0443 |
| Haemoglobin < 13 mg/dL | 174 (28.3) | 656 (21.4) | .0002 |  |  |
| Prior CVD | 399 (60.4) | 1372 (42.1) | <.0001 | 0.53 (0.42-0.67) | <.0001 |
| Prior MI | 213 (32.6) | 730 (22.5) | <.0001 |  |  |
| Prior PCI | 165 (25.2) | 710 (21.9) | .0645 |  |  |
| Prior CABG | 120 (18.2) | 267 (8.2) | <.0001 | 0.45 (0.32-0.63) | <.0001 |
| Heart failure | 46 (7.0) | 158 (4.9) | .027 |  |  |
| Arial fibrillation | 54 (8.2) | 158 (4.9) | .0006 |  |  |
| TIA/stroke | 48 (7.3) | 197 (6.1) | .2363 |  |  |
| PVD | 62 (9.5) | 212 (6.6) | .0087 |  |  |
| Aspirin | 365 (54.6) | 1347 (41.0) | <.0001 |  |  |
| Clopidogrel | 112 (16.8) | 435 (13.3) | .0167 |  |  |
| Anticoagulants | 34 (5.1) | 122 (3.7) | .0975 |  |  |
| ACE inhibitors/ARBs | 316 (47.4) | 1358 (41.5) | .0048 |  |  |
| Beta-blocker | 303 (45.3) | 1208 (36.9) | <.0001 |  |  |
| Statins | 301 (45.0) | 1272 (38.8) | .0029 |  |  |
| **Presence of catheterization laboratory in hospital** | 579 (86.5) | 2775 (84.5) | .1733 |  |  |
| **Terms relating-hospital level clustering** |  |  |  |  |  |
| Standard deviation of random effect term |  |  |  | 0.83 | <.0001 |

Medications are chronic CV medications (ie, patients were taking these before index event).

\*Terms selected using stepwise variable selection, except hospital type and geographical region which are forced into the multivariate model

95%CI, 95% confidence interval; ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; CABG, coronary artery bypass graft; CV, cardiovascular; CVD, cardiovascular disease; MI, myocardial infarction; NSTEACS, non-ST-segment elevation acute coronary syndrome; NSTEMI, non-ST-segment elevation myocardial infarction; PAD, peripheral arterial disease; PCI, percutaneous coronary intervention; TIA, transient ischemic attack.

**Table 3 of the Supplementary Material.** Hazard Ratios for All-cause Death for Subgroups of Medically Managed Versus Revascularised NSTEACS Patients by Management Strategy

|  |  |  |  |
| --- | --- | --- | --- |
| **Treatment** | **Model 1** | **Model 2** | **Model 3** |
| **Medical management** |  |  |  |
| Coronary revascularisation | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) |
| CAG- | 3.30 (2.54-4.27) | 2.52 (1.94-3.27) | 1.81 (1.23-2.65) |
| CAG+ CAD+ | 2.12 (1.54-2.92) | 1.88 (1.36-2.58) | 1.90 (1.23-2.95) |
| CAG+ CAD- | 0.86 (0.50-1.47) | 0.96 (0.56-1.64) | 0.68 (0.21-2.21) |
| **Type of hospital** |  |  |  |
| University general | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) |
| Non-university general | 1.08 (0.81-1.44) | 1.06 (0.80-1.41) | 1.01 (0.69-1.48) |
| Private | 0.89 (0.58-1.36) | 0.77 (0.50-1.19) | 0.48 (0.23-0.98) |
| Regional hospital | 0.95 (0.69-1.31) | 0.89 (0.65-1.23) | 0.95 (0.62-1.46) |
| **Geographical region** |  |  |  |
| Western Europe (North) | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) |
| Western Europe (South) | 1.43 (1.03-1.99) | 1.31 (0.94-1.83) | 1.82 (1.07-3.11) |
| Eastern Europe | 1.33 (0.96-1.85) | 1.86 (1.33-2.58) | 2.09 (1.24-3.53) |
| Latin America | 1.51 (1.06-2.15) | 1.94 (1.36-2.76) | 3.55 (1.98-6.37) |
| **EPICOR predictors of mortality** |  |  |  |
| Age (per 10 years) | - | 1.95 (1.75-2.17) | 1.53 (1.30-1.80) |
| Male gender | - | 0.73 (0.58-0.93) | 0.72 (0.50-1.03) |
| LVEF (per 10% higher) | - | - | 0.97 (0.96-0.98) |
| EQ5D (per unit higher) | - | - | 1.13 (1.04-1.22) |
| Serum creatinine (< 1.2 mg/dL) | - | - | 1.18 (0.84-1.66) |
| Glucose > 160 mg/dL | - | - | 1.39 (1.00-1.93) |
| Chronic obstructive pulmonary disease | - | - | 0.95 (0.57-1.59) |
| Haemoglobin < 13g/dL | - | - | 1.91 (1.36-2.67) |
| Peripheral vascular disease | - | - | 0.96 (0.59-1.56) |
| On diuretics at discharge | - | - | 1.56 (1.10-2.21) |
| **Terms relating-hospital level clustering of events** |  |  |
| Estimated gamma frailty term  | 0.16 | 0.15 | 0.07 |
| P-value for shared frailty | .023 | .027 | .30 |

CAD, coronary artery disease; CAG, coronary angiography; LVEF, left ventricular ejection fraction; NSTEACS, non ST-segment elevated acute coronary syndrome.